Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia
Background: Breast cancer is highly prevalent worldwide and leads to high health-care costs. HER2-positive subtype represents 30% of all breast cancers and is associated with a poor prognosis. Patients treated with anti-HER2 therapies frequently develop resistance and require pharmacological treatme...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2020
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23699
- Acceso en línea:
- https://doi.org/10.2147/CEOR.S220726
https://repository.urosario.edu.co/handle/10336/23699
- Palabra clave:
- Circulating tumor DNA
Docetaxel
Pertuzumab
Trastuzumab
Advanced cancer
Cancer chemotherapy
Cancer resistance
Colombia
Cost effectiveness analysis
DNA determination
Health care cost
Human
Human epidermal growth factor receptor 2 positive breast cancer
Liquid biopsy
Quality adjusted life year
Review
Sensitivity and specificity
Treatment outcome
Biomarkers
Breast cancer
Cost-effectiveness
Liquid biopsy
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_0edd89a5a12b59994c932945abdf67e6 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/23699 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia |
title |
Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia |
spellingShingle |
Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia Circulating tumor DNA Docetaxel Pertuzumab Trastuzumab Advanced cancer Cancer chemotherapy Cancer resistance Colombia Cost effectiveness analysis DNA determination Health care cost Human Human epidermal growth factor receptor 2 positive breast cancer Liquid biopsy Quality adjusted life year Review Sensitivity and specificity Treatment outcome Biomarkers Breast cancer Cost-effectiveness Liquid biopsy |
title_short |
Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia |
title_full |
Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia |
title_fullStr |
Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia |
title_full_unstemmed |
Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia |
title_sort |
Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia |
dc.subject.keyword.spa.fl_str_mv |
Circulating tumor DNA Docetaxel Pertuzumab Trastuzumab Advanced cancer Cancer chemotherapy Cancer resistance Colombia Cost effectiveness analysis DNA determination Health care cost Human Human epidermal growth factor receptor 2 positive breast cancer Liquid biopsy Quality adjusted life year Review Sensitivity and specificity Treatment outcome Biomarkers Breast cancer Cost-effectiveness Liquid biopsy |
topic |
Circulating tumor DNA Docetaxel Pertuzumab Trastuzumab Advanced cancer Cancer chemotherapy Cancer resistance Colombia Cost effectiveness analysis DNA determination Health care cost Human Human epidermal growth factor receptor 2 positive breast cancer Liquid biopsy Quality adjusted life year Review Sensitivity and specificity Treatment outcome Biomarkers Breast cancer Cost-effectiveness Liquid biopsy |
description |
Background: Breast cancer is highly prevalent worldwide and leads to high health-care costs. HER2-positive subtype represents 30% of all breast cancers and is associated with a poor prognosis. Patients treated with anti-HER2 therapies frequently develop resistance and require pharmacological treatment change. Liquid biopsy is a minimally invasive and an easily accessible technique, with high sensitivity and specificity, to detect molecular treatment resistance even before the onset of clinical manifestations and can thus be used to reduce unnecessary anti-HER2 treatment costs. Objective: To evaluate the cost-effectiveness of using liquid biopsy (ctDNA detection) to determine treatment change in women with HER2-positive advanced breast cancer in Colombia. Methodology: We performed an economic evaluation using decision tree modeling and deterministic analyses based on literature search for first and second lines of treatment (trastuzumab, pertuzumab, docetaxel, and TDM1); resistance; outcomes; and sensitivity and specificity of tests detecting molecular resistance. The effectiveness was measured using quality-adjusted life year (QALY) score, and costs were obtained from databases with national validity, suppliers, the Colombian Drug Price Information System (SISMED), and local studies. Results: The use of liquid biopsy (ctDNA detection) with conventional treatment was more expensive and less effective than conventional treatment without liquid biopsy (US $177,985.35 and 0.533889206 QALY, respectively). The incremental cost with liquid biopsy was US $7,333.17 and the incremental effectiveness was 0.00042256 QALY relative to the conventional method. Conclusion: Including liquid biopsy in the treatment of HER2-positive advanced breast cancer was considered currently inapplicable in Colombia because it was not cost effective. Our results open a window of opportunity to improve the development and implementation of ctDNA testing in Colombia, potentially reducing current costs. More evidence is required on the utility of this test, depending on the financial capacity of Colombia and other countries. © 2020 Sánchez-Calderón et al. |
publishDate |
2020 |
dc.date.accessioned.none.fl_str_mv |
2020-05-26T00:04:37Z |
dc.date.available.none.fl_str_mv |
2020-05-26T00:04:37Z |
dc.date.created.spa.fl_str_mv |
2020 |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.2147/CEOR.S220726 |
dc.identifier.issn.none.fl_str_mv |
11786981 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/23699 |
url |
https://doi.org/10.2147/CEOR.S220726 https://repository.urosario.edu.co/handle/10336/23699 |
identifier_str_mv |
11786981 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
122 |
dc.relation.citationStartPage.none.fl_str_mv |
115 |
dc.relation.citationTitle.none.fl_str_mv |
ClinicoEconomics and Outcomes Research |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 12 |
dc.relation.ispartof.spa.fl_str_mv |
ClinicoEconomics and Outcomes Research, ISSN:11786981, Vol.12,(2020); pp. 115-122 |
dc.relation.uri.spa.fl_str_mv |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079547351&doi=10.2147%2fCEOR.S220726&partnerID=40&md5=f782b3261340400a49f497ca4a0416b6 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Dove Medical Press Ltd |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
bitstream.url.fl_str_mv |
https://repository.urosario.edu.co/bitstreams/eb2e6ea8-2c17-4cec-b99c-06e7ffc2f697/download https://repository.urosario.edu.co/bitstreams/6c510869-8f51-448e-a38b-5affa11bd1f0/download https://repository.urosario.edu.co/bitstreams/20c2ceb2-862b-4366-8a2e-20079fe55080/download |
bitstream.checksum.fl_str_mv |
483b40b0c0aff1f8ccbb785a186bc789 b5e587a1c6aa45e88d6d973a25b65e8a eb01b786d7485dcf7c1bd9cac41b7374 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167662581776384 |
spelling |
80d4ee61-a3ca-497b-8f6f-be48ff136a67-1ad4c837c-0311-427e-897a-c4adc62f45b7-159e27360-9c0e-481b-88a6-783a51494570-184b1412d-896a-49ac-9ab1-ad7269e08f88-1317f0441-dd18-4c14-abe4-a7b1a276141e-10fbf1e78-a085-4513-97ac-58d5e2ff8ccc-12020-05-26T00:04:37Z2020-05-26T00:04:37Z2020Background: Breast cancer is highly prevalent worldwide and leads to high health-care costs. HER2-positive subtype represents 30% of all breast cancers and is associated with a poor prognosis. Patients treated with anti-HER2 therapies frequently develop resistance and require pharmacological treatment change. Liquid biopsy is a minimally invasive and an easily accessible technique, with high sensitivity and specificity, to detect molecular treatment resistance even before the onset of clinical manifestations and can thus be used to reduce unnecessary anti-HER2 treatment costs. Objective: To evaluate the cost-effectiveness of using liquid biopsy (ctDNA detection) to determine treatment change in women with HER2-positive advanced breast cancer in Colombia. Methodology: We performed an economic evaluation using decision tree modeling and deterministic analyses based on literature search for first and second lines of treatment (trastuzumab, pertuzumab, docetaxel, and TDM1); resistance; outcomes; and sensitivity and specificity of tests detecting molecular resistance. The effectiveness was measured using quality-adjusted life year (QALY) score, and costs were obtained from databases with national validity, suppliers, the Colombian Drug Price Information System (SISMED), and local studies. Results: The use of liquid biopsy (ctDNA detection) with conventional treatment was more expensive and less effective than conventional treatment without liquid biopsy (US $177,985.35 and 0.533889206 QALY, respectively). The incremental cost with liquid biopsy was US $7,333.17 and the incremental effectiveness was 0.00042256 QALY relative to the conventional method. Conclusion: Including liquid biopsy in the treatment of HER2-positive advanced breast cancer was considered currently inapplicable in Colombia because it was not cost effective. Our results open a window of opportunity to improve the development and implementation of ctDNA testing in Colombia, potentially reducing current costs. More evidence is required on the utility of this test, depending on the financial capacity of Colombia and other countries. © 2020 Sánchez-Calderón et al.application/pdfhttps://doi.org/10.2147/CEOR.S22072611786981https://repository.urosario.edu.co/handle/10336/23699engDove Medical Press Ltd122115ClinicoEconomics and Outcomes ResearchVol. 12ClinicoEconomics and Outcomes Research, ISSN:11786981, Vol.12,(2020); pp. 115-122https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079547351&doi=10.2147%2fCEOR.S220726&partnerID=40&md5=f782b3261340400a49f497ca4a0416b6Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURCirculating tumor DNADocetaxelPertuzumabTrastuzumabAdvanced cancerCancer chemotherapyCancer resistanceColombiaCost effectiveness analysisDNA determinationHealth care costHumanHuman epidermal growth factor receptor 2 positive breast cancerLiquid biopsyQuality adjusted life yearReviewSensitivity and specificityTreatment outcomeBiomarkersBreast cancerCost-effectivenessLiquid biopsyAnalysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in ColombiaarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Sánchez-Calderón, DianaPedraza, AdrianaMancera Urrego, CatalinaMejía-Mejía, AurelioMontealegre-Páez, Ana LorenaPerdomo, SandraORIGINALceor-220726-analysis-of-the-cost-effectiveness-of-liquid-biopsy-to-deter.pdfapplication/pdf1174590https://repository.urosario.edu.co/bitstreams/eb2e6ea8-2c17-4cec-b99c-06e7ffc2f697/download483b40b0c0aff1f8ccbb785a186bc789MD51TEXTceor-220726-analysis-of-the-cost-effectiveness-of-liquid-biopsy-to-deter.pdf.txtceor-220726-analysis-of-the-cost-effectiveness-of-liquid-biopsy-to-deter.pdf.txtExtracted texttext/plain39595https://repository.urosario.edu.co/bitstreams/6c510869-8f51-448e-a38b-5affa11bd1f0/downloadb5e587a1c6aa45e88d6d973a25b65e8aMD52THUMBNAILceor-220726-analysis-of-the-cost-effectiveness-of-liquid-biopsy-to-deter.pdf.jpgceor-220726-analysis-of-the-cost-effectiveness-of-liquid-biopsy-to-deter.pdf.jpgGenerated Thumbnailimage/jpeg4392https://repository.urosario.edu.co/bitstreams/20c2ceb2-862b-4366-8a2e-20079fe55080/downloadeb01b786d7485dcf7c1bd9cac41b7374MD5310336/23699oai:repository.urosario.edu.co:10336/236992022-05-02 07:37:21.204093https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |